Processa Pharmaceuticals, Inc. PCSA
We take great care to ensure that the data presented and summarized in this overview for Processa Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PCSA
Top Purchases
Top Sells
About PCSA
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Insider Transactions at PCSA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2024
|
James H Stanker Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-4.17%
|
$282
$1.71 P/Share
|
|
Jul 10
2024
|
James H Stanker Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+8.69%
|
-
|
|
Jul 10
2024
|
Sian Bigora Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-1.02%
|
$225
$1.71 P/Share
|
|
Jul 10
2024
|
Sian Bigora Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+2.83%
|
-
|
|
Jul 10
2024
|
Patrick Lin Chief Business - Strategy Off |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-0.92%
|
$271
$1.71 P/Share
|
|
Jul 10
2024
|
Patrick Lin Chief Business - Strategy Off |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+2.15%
|
-
|
|
Jul 10
2024
|
David Young Pres. Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-0.35%
|
$282
$1.71 P/Share
|
|
Jul 10
2024
|
David Young Pres. Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.79%
|
-
|
|
Jul 10
2024
|
Wendy Guy Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
220
-1.82%
|
$220
$1.71 P/Share
|
|
Jul 10
2024
|
Wendy Guy Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+5.06%
|
-
|
|
Apr 05
2024
|
James H Stanker Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
518
-7.8%
|
$1,036
$2.79 P/Share
|
|
Apr 05
2024
|
James H Stanker Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+20.15%
|
-
|
|
Apr 05
2024
|
Sian Bigora Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-1.69%
|
$736
$2.79 P/Share
|
|
Apr 05
2024
|
Sian Bigora Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+7.13%
|
-
|
|
Apr 05
2024
|
Patrick Lin Chief Business - Strategy Off |
SELL
Payment of exercise price or tax liability
|
Direct |
539
-1.84%
|
$1,078
$2.79 P/Share
|
|
Apr 05
2024
|
Patrick Lin Chief Business - Strategy Off |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+5.42%
|
-
|
|
Apr 05
2024
|
David Young Pres. Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
518
-0.64%
|
$1,036
$2.79 P/Share
|
|
Apr 05
2024
|
David Young Pres. Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+2.02%
|
-
|
|
Apr 05
2024
|
Wendy Guy Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-3.12%
|
$736
$2.79 P/Share
|
|
Apr 05
2024
|
Wendy Guy Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+12.43%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 20K shares |
|---|---|
| Open market or private purchase | 63K shares |
| Payment of exercise price or tax liability | 5.9K shares |
|---|